RxDoctor Payments Data

Sonnel Patrick, MD

Allergy & Immunology · Waterbury, CTNPI 1184698565

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novartis at 24.3% of the total.

$2,256in general payments, 2019–2025

Across 109 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$548
  • GSK$286
  • Genentech USA, Inc.$237
  • Sanofi$175
  • Regeneron Healthcare Solutions, Inc.$133
  • AbbVie$131
  • plus $745 from 17 others

What the payments were for

  • Food & beverage$2,22899%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,256 in reported general payments places this provider in the 55th percentile of 54 allergy & immunology providers in Connecticut.

See all allergy & immunology providers in Connecticut

Medicare billing

Part B allowed, 2024
$57,497
Medicare patients
103
Services billed
3,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol18$9,616
SymbicortBudesonide/Formoterol Fumarate28$9,120
Arnuity ElliptaFluticasone Furoate29$7,359
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,243
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$5,856
Qvar RedihalerBeclomethasone Dipropionate17$4,774
AlvescoCiclesonide17$4,410
Levocetirizine Dihydrochloride414$3,596
Azelastine Hcl98$2,515
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,368
Fluticasone Propionate130$1,612
Wixela InhubFluticasone Propion/Salmeterol30$1,591
Epinephrine16$1,330
Albuterol Sulfate HfaAlbuterol Sulfate60$1,094
Hydroxyzine Hcl62$1,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Arnuity Ellipta, Trelegy Ellipta$286$23,21758 claims
AstraZenecaSymbicort$70$9,12028 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$15$4,77417 claims
Covis Pharma GmbHAlvesco$38$4,41017 claims
Hikma Pharmaceuticals USAEpinephrine$14$1,33016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 54 allergy & immunology providers in Connecticut.

Other allergy & immunology in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →